Optimizing Secukinumab Treatment in Psoriasis with Concomitant Methotrexate Administration: Minireview and A Case Report.

Methotrexate concomitant therapy Psoriasis Psoriatic arthritis Secukinumab

Journal

Case reports in dermatology
ISSN: 1662-6567
Titre abrégé: Case Rep Dermatol
Pays: Switzerland
ID NLM: 101517685

Informations de publication

Date de publication:
Historique:
received: 02 07 2019
accepted: 03 07 2019
entrez: 31 10 2019
pubmed: 31 10 2019
medline: 31 10 2019
Statut: epublish

Résumé

The introduction of biologic drugs for the treatment of moderate-to-severe psoriasis resulted in a significant improvement in patients' health. Moreover, treatment regimens in psoriatic patients should be tailored to meet specific needs based on disease severity, impact on quality of life, response to previous therapies and presence of comorbidities. Combination therapy of biologic agents with conventional systemic drugs has been proposed to optimize psoriasis treatment outcomes in unresponsive or partial responsive severe psoriatic patients. We report the case of a patient with a long-standing recalcitrant plaque psoriasis and psoriatic arthritis who was administered secukinumab combined with methotrexate. The patient had previously been treated with several topical and systemic therapies associated with loss of efficacy or adverse event occurrence. Approximately 24 weeks after starting the combined regimen, significant clearance of psoriasis and reduction of arthritis ensued, with no drug side effects.

Identifiants

pubmed: 31662734
doi: 10.1159/000501994
pii: cde-0011-0017
pmc: PMC6816129
doi:

Types de publication

Case Reports

Langues

eng

Pagination

17-22

Informations de copyright

Copyright © 2019 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare.

Références

Dermatol Ther (Heidelb). 2018 Mar;8(1):57-68
pubmed: 29392570
JAAD Case Rep. 2018 Mar 31;4(4):310-313
pubmed: 29693056
Arthritis Care Res (Hoboken). 2015 May;67(5):624-32
pubmed: 25370912
Int J Mol Sci. 2017 Nov 01;18(11):null
pubmed: 29104241
Am J Clin Dermatol. 2014 Dec;15(6):467-78
pubmed: 25373522
J Am Acad Dermatol. 2005 Feb;52(2):262-7
pubmed: 15692471
Acta Derm Venereol. 2010 Jul;90(4):341-9
pubmed: 20574597
J Am Acad Dermatol. 2019 Jan;80(1):27-40
pubmed: 30017705
J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507-1514
pubmed: 29444376
J Drugs Dermatol. 2016 May 1;15(5):648-9
pubmed: 27168275
Br J Dermatol. 2017 Mar;176(3):752-758
pubmed: 27518376
Am J Clin Dermatol. 2015 Aug;16(4):285-294
pubmed: 25963062

Auteurs

Dimitra Kostaki (D)

Department of Dermatology, University of Rome, "La Sapienza", Rome, Italy.

Emilia Aquila (E)

Department of Dermatology, University of Rome, "La Sapienza", Rome, Italy.

Laura Macaluso (L)

Department of Dermatology, University of Rome, "La Sapienza", Rome, Italy.

Carlo Mattozzi (C)

Department of Dermatology, University of Rome, "La Sapienza", Rome, Italy.

Antonio Giovanni Richetta (AG)

Department of Dermatology, University of Rome, "La Sapienza", Rome, Italy.

Classifications MeSH